Company intelligence / Profile preview
Anda Biopharmaceutical Development
Beijing, China
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Anda Biopharmaceutical Development has at least two personalized neoantigen vaccine programs in Phase 1 trials for pancreatic ductal adenocarcinoma and pancreatic cancer. The pipeline is focused on neoplasms and metabolic diseases, with an emphasis on novel vaccine-based immunotherapies. No published Phase 2 or later clinical data as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Personalized antigen vaccineTherapeutic vaccineVaccine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Anda Biopharmaceutical Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anda Biopharmaceutical Development.